Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/200498COMBINATION THERAPY WITH AN ANTI-CA19-9 ANTIBODY AND FOLFIRINOX IN THE TREATMENT OF CANCER
WO 29.09.2022
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No PCT/EP2022/057771 Applicant BIONTECH SE Inventor HASSAN, Hariz
The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CAI 9-9, including cancer diseases such as pancreatic cancer and metastases thereof.
2.WO/2022/201053PROTEINS COMPRISING CD3 ANTIGEN BINDING DOMAINS AND USES THEREOF
WO 29.09.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/IB2022/052646 Applicant JANSSEN BIOTECH, INC. Inventor ZWOLAK, Adam
The disclosure provides antigen binding domains that bind cluster of differentiation 3 (CD3) protein, comprising the antigen binding domains that bind CD3ε, polynucleotides encoding them, vectors, host cells, methods of making and using them.
3.WO/2022/200303METHODS FOR THE DIAGNOSIS AND TREATMENT OF T CELL-LYMPHOMAS
WO 29.09.2022
Int.Class A61P 35/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
Appl.No PCT/EP2022/057408 Applicant INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Inventor BENSUSSAN, Armand
T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sezary syndrome are the most frequent cutaneous T-cell lymphomas. The inventors studied the regulatory T phenotype of Sezary cells and showed the expression of CCR8 (CD198) by Sezary cells and other T-cell lymphoma cell lines. CCR8 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas. Therapeutic depletion of CCR8-expressing cancer cells would eliminate tumor cells and also activate the anti-tumor immunity in T-cell lymphomas.
4.WO/2022/204443EFFICIENT TCR GENE EDITING IN T LYMPHOCYTES
WO 29.09.2022
Int.Class C07K 14/725
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
Appl.No PCT/US2022/021820 Applicant GENENTECH, INC. Inventor RUTZ, Sascha
The present disclosure relates to engineered T cells and methods of making and using the same, as well as reagents for making the engineered T cells.
5.WO/2022/203963CORONAVIRUS VACCINE FORMULATIONS
WO 29.09.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2022/020974 Applicant NOVAVAX, INC. Inventor SMITH, Gale
Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
6.WO/2022/202853EFFICACIOUS ANTI-CD26 ANTIBODY BIOMARKER
WO 29.09.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/JP2022/013309 Applicant Y'S AC CO., LTD. Inventor MORIMOTO, Chikao
In the present invention, a potential prognostic biomarker for CD26-targeted therapy was identified based on phase I trial data of the humanized anti-CD26 monoclonal antibody YS110 for CD26-expressing tumors. Box-and-whisper plot analysis, scatter plot analysis, Pearson's product-moment correlation/Spearman's rank-order correlation, bar graph analysis and receiver operating characteristics (ROC) were used to examine the correlation between soluble CD26 titer variation with YS110 administration and tumor volume change, RECIST criteria evaluation and progression free survival (PFS). The mechanism for serum soluble CD26 titer variation was confirmed by in vitro experimentation. As a result, it was discovered, for the first time, that serum soluble CR26/DPP4 titer variation in the early stage of YS110 treatment is a predictive biomarker for evaluating thereapeutic effect.
7.WO/2022/204293SELECTIVE TARGETING OF OLIGOMERIC Β‑AMYLOID
WO 29.09.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2022/021567 Applicant ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY Inventor HE, Ping
The invention provides methods and compositions for treating or ameliorating Alzheimer's disease. The invention provides agents that reduce Aβ inclusions and plaque accumulation, inhibit dendrite spine loss, and restore neurogenesis.
8.WO/2022/204308MULTISOME LIPID VESICLES FOR DELIVERY OF COSMETIC AGENTS
WO 29.09.2022
Int.Class C07K 7/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
08having 12 to 20 amino acids
Appl.No PCT/US2022/021585 Applicant GLO PHARMA, INC. Inventor FOLDVARI, Marianna
The present invention relates to compositions comprising and methods for use of formulations for the delivery of cosmetic agents, including anionic polymers such as hyaluronic acid and peptides with cosmetic activity. They are useful in, e.g., cosmetics and pharmaceuticals that prevent or improve the appearance of undesirable skin features including wrinkles or enhancing lip fullness.
9.20220307015COMPOSITIONS AND METHODS FOR IDENTIFYING REGULATORS OF CELL TYPE FATE SPECIFICATION
US 29.09.2022
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
Appl.No 17636750 Applicant Duke University Inventor Charles A. Gersbach

Disclosed herein are compositions, methods, and systems for selecting a polynucleotide for activity as a neuronal-specific transcription factor. The system may include a polynucleotide encoding a reporter protein and a pan-neuronal marker, a Gas protein, and a library of guide RNAs (gRNAs) targeting putative transcription factors. Further provided are methods of screening for a neuronal-specific transcription factor.

10.20220307048ANTIMICROBIAL PEPTIDES
US 29.09.2022
Int.Class C12N 15/82
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
82for plant cells
Appl.No 17700591 Applicant Genvor Inc. Inventor Jesse Michael Jaynes

The present invention includes an antimicrobial peptide consisting of, consisting essentially of, or comprising, at least one of SEQ ID NO:1-20, nucleic acids encoding the peptides, methods for using the antimicrobial peptide generating plants which express the peptides sufficient to endow the plants with resistance to pathogenic bacteria and fungi, the use of the nucleic acids to produce peptides by cellular production such as fermentation or plant production systems of the antimicrobial peptide(s), and the use of the isolated antimicrobial peptide(s) in a spray or other mixture to treat plants to protect them from disease.